Praxis Precision Medicines, Inc.

NasdaqGS:PRAX 株式レポート

時価総額：US$1.4b

Praxis Precision Medicines マネジメント

マネジメント 基準チェック /44

Praxis Precision Medicinesの CEO はMarcio De'Souzaで、 Apr2020年に任命され、 の在任期間は 4.58年です。 の年間総報酬は$ 2.12Mで、 29.5%給与と70.5%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.089%を直接所有しており、その価値は$ 1.27M 。経営陣と取締役会の平均在任期間はそれぞれ3.9年と3年です。

主要情報

Marcio De'Souza

最高経営責任者

US$2.1m

報酬総額

CEO給与比率29.5%
CEO在任期間4.6yrs
CEOの所有権0.09%
経営陣の平均在職期間3.9yrs
取締役会の平均在任期間3yrs

経営陣の近況

Recent updates

Praxis Precision Medicines: Great Price Movement, But Still Not Convinced

Oct 13

We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely

Aug 30
We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely

Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth

May 14
Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth

Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing

Mar 26

Is There An Opportunity With Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) 26% Undervaluation?

Feb 27
Is There An Opportunity With Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) 26% Undervaluation?

Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely

Nov 29
Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely

Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?

Aug 14
Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?

Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?

Feb 10
Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?

Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely

Oct 21
Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely

Praxis Precision Medicines GAAP EPS of -$1.32 misses by $0.02

Aug 08

Praxis: MDD Trial Failure May Not Mean An End To Entire Pipeline

Jun 10

We're Keeping An Eye On Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

May 15
We're Keeping An Eye On Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth

Jan 27
Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth

Praxis Precision Medicines: Genetic Medicines For Neurological Disease

Nov 23

We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

Oct 14
We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

Praxis' PRAX-562 wins Orphan Drug designation for rare encephalopathy

Apr 30

Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth

Mar 12
Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth

Read This Before Selling Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares

Jan 18
Read This Before Selling Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares

Praxis Precision's pediatric epilepsy therapies nab Rare Pediatric and Orphan Drug tags in U.S.

Jan 07

Praxis Precision Medicine plummets 27% on clinical hold on lead drug

Nov 10

CEO報酬分析

Praxis Precision Medicines の収益と比較して、Marcio De'Souza の報酬はどのように変化したか？
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$151m

Jun 30 2024n/an/a

-US$124m

Mar 31 2024n/an/a

-US$125m

Dec 31 2023US$2mUS$625k

-US$123m

Sep 30 2023n/an/a

-US$138m

Jun 30 2023n/an/a

-US$157m

Mar 31 2023n/an/a

-US$183m

Dec 31 2022US$6mUS$625k

-US$214m

Sep 30 2022n/an/a

-US$231m

Jun 30 2022n/an/a

-US$232m

Mar 31 2022n/an/a

-US$208m

Dec 31 2021US$11mUS$571k

-US$167m

Sep 30 2021n/an/a

-US$135m

Jun 30 2021n/an/a

-US$111m

Mar 31 2021n/an/a

-US$88m

Dec 31 2020US$12mUS$385k

-US$70m

報酬と市場: Marcioの 総報酬 ($USD 2.12M ) は、 US市場 ($USD 5.42M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Marcioの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Marcio De'Souza (45 yo)

4.6yrs

在職期間

US$2,120,512

報酬

Mr. Marcio Silva De'Souza has been President, Chief Executive Officer and Director of Praxis Precision Medicines, Inc. since April 2020. Mr. De'Souza joined the Praxis Precision Medicines, Inc. in April 20...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Marcio De'Souza
President4.6yrsUS$2.12m0.089%
$ 1.3m
Timothy Kelly
CFO & Treasurer3.5yrsUS$1.02m0.019%
$ 272.1k
Alex Nemiroff
General Counsel & Secretary4.4yrsUS$843.11k0.013%
$ 180.7k
Steven Petrou
Co-Founder & Chief Scientific Officer6.8yrsデータなしデータなし
Lauren Mastrocola
VP of Finance & Principal Accounting Officerno dataデータなし0.0085%
$ 122.2k
Karl Hansen
Chief Technical Operations Officer2.9yrsデータなしデータなし
Alex Kane
VP of Investor Relations & Corporate Communicationsno dataデータなしデータなし
Kelly McCue
Chief People Officer3.9yrsデータなし0.016%
$ 225.5k
Alyssa J. Wyant
Chief Regulatory & Quality Officer4.2yrsデータなしデータなし
Megan Sniecinski
Chief Business Officer2.9yrsデータなしデータなし
Brian Spar
Chief of Staff2.7yrsデータなしデータなし

3.9yrs

平均在職期間

45yo

平均年齢

経験豊富な経営陣: PRAXの経営陣は 経験豊富 であると考えられます ( 3.9年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Marcio De'Souza
President4.6yrsUS$2.12m0.089%
$ 1.3m
William Young
Independent Director7.9yrsUS$79.28k0.010%
$ 145.9k
Dean Mitchell
Independent Chairman of the Board4.2yrsUS$104.37k0.027%
$ 384.4k
Gregory Norden
Independent Director5.7yrsUS$82.87k0.0010%
$ 14.5k
Merit Cudkowicz
Independent Director3.6yrsUS$76.28k0%
$ 0
Jill DeSimone
Independent Director2.5yrsUS$78.87k0.0052%
$ 74.2k
Jeffrey Chodakewitz
Independent Director3.6yrsUS$72.87k0%
$ 0
Anna Greka
Member of Scientific Advisory Board1.8yrsデータなしデータなし
Matthew Might
Chairman of the Scientific Advisory Board1.8yrsデータなしデータなし
Holger Lerche
Member of Scientific Advisory Board1.8yrsデータなしデータなし
Ivan Soltesz
Member of Scientific Advisory Board1.8yrsデータなしデータなし
Samuel Berkovic
Member of Scientific Advisory Board1.8yrsデータなしデータなし

3.0yrs

平均在職期間

68yo

平均年齢

経験豊富なボード: PRAXの 取締役会 は 経験豊富 であると考えられます ( 3年の平均在任期間)。